Orally Administered Bioadherent Sustained Release Microencapsulated Vaccines
Final rept. 14 Aug 1995-14 Aug 1996
LYNNTECH INC COLLEGE STATION TX
Pagination or Media Count:
This SBIR Phase I research project focuses on the development of an orally administered microencapsulated vaccine against staphylococcal enterotoxin A SEA. The research is centered around using a known broadhesive, vitelline protein B vpB, to increase contact time with the gut and enhance absorption of the microspheres by the Peyers patches of the gut-associated lymphoid tissues. Results clearly show that orally administered SEA containing microspheres produce a greater immune response than orally administered nonencapsulated SEA. - When vpB is coencapsulated with SEA into BSA microspheres the resulting immune response to SEA is less than microspheres that contain only SEA and BSA. However, when vpB is coencapsulated with SEA into polyDL- lactide-co-glycolide PLO microspheres the resulting immune response to SEA is greater than microspheres that contain only SEA and PLG. Whether vpB is acting as a true bioadhesive when included in PLO microspheres is not clear. It is first necessary to determine how the presence of vpB affects release rate from and surface hydrophobicity of PLO microspheres since both of these parameters can greatly affect immune response to SEA.
- Medicine and Medical Research